FOR IMMEDIATE RELEASE

Company Name	Kyowa Kirin Co., Ltd.
Representative	Abdul Mullick, President and COO
	(Code No. 4151, TSE Prime)
Inquiries	Hiroki Nakamura, Executive Vice President,
	Corporate Communications Department
	Media Contact: +81-3-5205-7205
	Investor Contact: +81-3-5205-7206

(Correction / Correction of Numerical Data)
Partial Correction of "Consolidated Financial Summary Fiscal 2025"

Tokyo, Japan, March 9, 2026 – Kyowa Kirin Co., Ltd. (hereinafter "Kyowa Kirin") hereby announces that the following corrections have been made to certain information in the Fiscal 2025" announced on February 9, 2026.

1. Reason for Corrections

This correction is made due to an error in the calculation process of "Purchase of property, plant and equipment" in the consolidated statement of cash flows.

2. Details of Corrections

Corrections are underlined in red below.

①Summary Information

1. Consolidated Financial Results for the Fiscal Year Ended December 31, 2025 (from January 1, 2025 to December 31, 2025)

(3) Consolidated cash flows

【Before Correction】

(3) Consolidated cash flows

	Net cash provided by (used in) operating activities	Net cash provided by (used in) investing activities	Net cash provided by (used in) financing activities	Cash and cash equivalents at end of period
Fiscal year ended	Millions of yen	Millions of yen	Millions of yen	Millions of yen
December 31, 2025	100,016	(92,586)	(36,853)	218,769
December 31, 2024	67,884	(142,387)	(84,697)	244,681

【After Correction】

(3) Consolidated cash flows

	Net cash provided by (used in) operating activities	Net cash provided by (used in) investing activities	Net cash provided by (used in) financing activities	Cash and cash equivalents at end of period
Fiscal year ended	Millions of yen	Millions of yen	Millions of yen	Millions of yen
December 31, 2025	96,619	(89,189)	(36,853)	218,769
December 31, 2024	67,884	(142,387)	(84,697)	244,681

②Attachment (Page 5, 24)

1. Summary of Business Performance and Financial Position

(3) Cash Flow Summary for Fiscal 2025

【Before Correction】

(3) Cash Flow Summary for Fiscal 2025

(Billions of yen)

	Fiscal year ended December 31, 2024	Fiscal year ended December 31, 2025	Year-on-year change	Rate of change (%)
Net cash provided by (used in) operating activities	67.9	100.0	32.1	47.3%
Net cash provided by (used in) investing activities	(142.4)	(92.6)	49.8	(35.0)%
Net cash provided by (used in) financing activities	(84.7)	(36.9)	47.8	(56.5)%
Cash and cash equivalents at beginning of period	403.1	244.7	(158.4)	(39.3)%
Cash and cash equivalents at end of period	244.7	218.8	(25.9)	(10.6)%

- Cash and cash equivalents as of December 31, 2025 were ¥218.8 billion, a decrease of ¥25.9 billion compared with the balance of ¥244.7 billion as of December 31, 2024.
  The main contributing factors affecting cash flow during the current fiscal year were as follows:
- Net cash provided by operating activities was ¥100.0 billion, compared with net cash provided by operating activities of ¥67.9 billion in the previous fiscal year. Major inflows were depreciation and amortization of ¥26.1 billion, in addition to profit before tax of ¥87.2 billion. Major outflows were an increase in trade receivables of ¥22.4 billion and a decrease in contract liabilities of ¥6.1 billion.
- Net cash used in investing activities was ¥92.6 billion, compared with net cash used in investing activities of ¥142.4 billion in the previous fiscal year. Major outflows were purchase of intangible assets of ¥45.8 billion, purchase of property, plant and equipment of ¥41.1 billion, and transfers to escrow account of ¥7.7 billion, which is a part of the construction funds for a new biopharmaceutical drug substance manufacturing building
- Net cash used in financing activities was ¥36.9 billion, compared with net cash used in financing activities of ¥84.7 billion in the previous fiscal year. Major outflows were dividends paid of ¥30.9 billion and repayments of lease liabilities of ¥6.0 billion.



【After Correction】

(3) Cash Flow Summary for Fiscal 2025

(Billions of yen)

	Fiscal year ended December 31, 2024	Fiscal year ended December 31, 2025	Year-on-year change	Rate of change (%)
Net cash provided by (used in) operating activities	67.9	96.6	28.7	42.3%
Net cash provided by (used in) investing activities	(142.4)	(89.2)	53.2	(37.4)%
Net cash provided by (used in) financing activities	(84.7)	(36.9)	47.8	(56.5)%
Cash and cash equivalents at beginning of period	403.1	244.7	(158.4)	(39.3)%
Cash and cash equivalents at end of period	244.7	218.8	(25.9)	(10.6)%

- Cash and cash equivalents as of December 31, 2025 were ¥218.8 billion, a decrease of ¥25.9 billion compared with the balance of ¥244.7 billion as of December 31, 2024.
  The main contributing factors affecting cash flow during the current fiscal year were as follows:
- Net cash provided by operating activities was ¥96.6 billion, compared with net cash provided by operating activities of ¥67.9 billion in the previous fiscal year. Major inflows were depreciation and amortization of ¥26.1 billion, in addition to profit before tax of ¥87.2 billion. Major outflows were an increase in trade receivables of ¥22.4 billion and a decrease in contract liabilities of ¥6.1 billion.
- Net cash used in investing activities was ¥89.2 billion, compared with net cash used in investing activities of ¥142.4 billion in the previous fiscal year. Major outflows were purchase of intangible assets of ¥45.8 billion, purchase of property, plant and equipment of ¥37.7 billion, and transfers to escrow account of ¥7.7 billion, which is a part of the construction funds for a new biopharmaceutical drug substance manufacturing building
- Net cash used in financing activities was ¥36.9 billion, compared with net cash used in financing activities of ¥84.7 billion in the previous fiscal year. Major outflows were dividends paid of ¥30.9 billion and repayments of lease liabilities of ¥6.0 billion.



3. Consolidated Financial Statements and Significant Notes Thereto

(4) Consolidated Statement of Cash Flows

【Before Correction】

(4) Consolidated Statement of Cash Flows

(Millions of yen)

	Fiscal year ended December 31, 2024	Fiscal year ended December 31, 2025
Cash flows from operating activities		
Profit before tax	83,453	87,221
Depreciation and amortization	24,780	26,144
Impairment losses (reversal of impairment losses)	2,060	2,772
Increase (decrease) in provisions	(203)	(2,824)
Share of loss (profit) of investments accounted for using equity method	(3,539)	(787)
Gain on sales of share and valuation of remaining share (gain)	(7,372)	–
Foreign exchange loss (gain)	8,347	3,800
Decrease (increase) in inventories	(1,646)	2,798
Decrease (increase) in trade receivables	(31,531)	(22,416)
Increase (decrease) in trade payables	(694)	(5,242)
Increase (decrease) in contract liabilities	(9,910)	(6,131)
Income taxes refund (paid)	(17,663)	204
Other	21,802	14,477
Net cash provided by (used in) operating activities	67,884	100,016
Cash flows from investing activities		
Purchase of property, plant and equipment	(26,037)	(41,112)
Proceeds from sale of property, plant and equipment	3,397	136
Purchase of intangible assets	(79,231)	(45,804)
Purchase of investments accounted for using equity method	–	(1,200)
Purchase of investment securities	(2,187)	(1,271)
Proceeds from sale of investment securities	2,892	277
Collection of loans receivable	4,503	–
Purchase of shares of subsidiaries resulting in change in scope of consolidation	(48,196)	–
Proceeds from sale of investments in subsidiaries resulting in change in scope of consolidation	1,343	–
Proceeds from redemption of bonds of subsidiaries and associates	1,000	4,000
Transfers to escrow account	–	(7,700)
Other	127	87
Net cash provided by (used in) investing activities	(142,387)	(92,586)

【After Correction】

(4) Consolidated Statement of Cash Flows

		(Millions of yen)
	Fiscal year ended December 31, 2024	Fiscal year ended December 31, 2025
Cash flows from operating activities		
Profit before tax	83,453	87,221
Depreciation and amortization	24,780	26,144
Impairment losses (reversal of impairment losses)	2,060	2,772
Increase (decrease) in provisions	(203)	(2,824)
Share of loss (profit) of investments accounted for using equity method	(3,539)	(787)
Gain on sales of share and valuation of remaining share (gain)	(7,372)	–
Foreign exchange loss (gain)	8,347	3,800
Decrease (increase) in inventories	(1,646)	2,798
Decrease (increase) in trade receivables	(31,531)	(22,416)
Increase (decrease) in trade payables	(694)	(5,242)
Increase (decrease) in contract liabilities	(9,910)	(6,131)
Income taxes refund (paid)	(17,663)	204
Other	21,802	11,080
Net cash provided by (used in) operating activities	67,884	96,619
Cash flows from investing activities		
Purchase of property, plant and equipment	(26,037)	(37,715)
Proceeds from sale of property, plant and equipment	3,397	136
Purchase of intangible assets	(79,231)	(45,804)
Purchase of investments accounted for using equity method	–	(1,200)
Purchase of investment securities	(2,187)	(1,271)
Proceeds from sale of investment securities	2,892	277
Collection of loans receivable	4,503	–
Purchase of shares of subsidiaries resulting in change in scope of consolidation	(48,196)	–
Proceeds from sale of investments in subsidiaries resulting in change in scope of consolidation	1,343	–
Proceeds from redemption of bonds of subsidiaries and associates	1,000	4,000
Transfers to escrow account	–	(7,700)
Other	127	87
Net cash provided by (used in) investing activities	(142,387)	(89,189)

END